Its important not to self-diagnose symptoms of a B12 deficiency can be quite general, so its good to get a comprehensive medical assessment to rule out other conditions and accurately diagnose a B12 deficiency
Conclusion The BPC-157 FDA approval status 2026 is unambiguous at the approval level: BPC-157 is not FDA approved, has no active IND, and has no registered human clinical trials
HMB (beta-hydroxy-beta-methylbutyrate) at about 3 g per day is a second adjunct: it is understood to activate the mTOR (mechanistic target of rapamycin) pathway and inhibit muscle protein breakdown, and a meta-analysis in older adults reported a modest standardized benefit, but the wider evidence is mixed and generally null in trained individuals capable of structured resistance exercise [1]
F., Jin, G
Applying twice a week and expecting results is unrealistic
References: FDA press statement (Feb 6, 2026): Understanding the risks of compounded drugs: Compounding when drugs are on FDAs drug shortages list: Compounding and the FDA, Questions and Answers: FDA guidance on Section 503A of the FD&C Act: #FDA #GLP1 #DrugSafety #CompoundingPharmacies #RegulatoryScience #PharmaCompliance #PublicHealth #Telehealth Disclaimer:This post is for informational purposes only and reflects a summary of publicly available information from the U.S